A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain
Status:
Terminated
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that using Cyproheptadine in a placebo-controlled crossover
trial would help relieve abdominal pain associated with (Functional Abdominal Pain (FAP) in
children, achieving a greater response than that observed with placebo. In addition to
assessing self-report of pain and other symptoms, the investigators also propose to perform
experimental somatic pain testing to determine if there is evidence of
peripherally-maintained central sensitization in children with FAP. The investigators also
hypothesize that there will be an increase in somatic pain threshold after completion of a
Cyproheptadine course compared to baseline testing prior to treatment, and compared to
placebo. This would allow children with FAP to return to normal function, improve symptoms
and overall general well-being